抗疟疾药物伯氨喹和氯喹有不同的敏化效果与Anti-mitotic药物耐药癌细胞。
文章的细节
-
引用
复制到剪贴板 -
崔AR,金正日JH,吸引YH, Kim HS Yoon年代
抗疟疾药物伯氨喹和氯喹有不同的敏化效果与Anti-mitotic药物耐药癌细胞。
外科杂志2016年4月,36 (4):1641 - 8。
- PubMed ID
-
27069141 (在PubMed]
- 文摘
-
本研究的目的是确定条件会增加耐药肿瘤细胞的敏感性。以前,两个抗疟药氯喹(背影)和伯氨喹(PRI),显示不同的敏化效果长春花碱(VIB)防癌症细胞。这里,我们测试了co-treatment背影或革命制度党和其他microtubule-targeting癌症细胞的药物,即vinorelbine (VIO),紫杉醇(PAC),多西他赛(DOC),长春新碱(VIC),或新药halaven (HAL)。我们发现,革命制度党敏化22 (P-gp) -overexpressing耐药KBV20C细胞所有六个anti-mitotic药物类似的程度。的背影有一个类似的敏化效果只有co-treatment PAC,医生,维克,和哈尔,而敏化效果不标记为co-treatment VIB和VIO。流式细胞仪分析和免疫印迹分析表明G2arrest和细胞凋亡与VIB co-treatment仅有小幅增长或VIO和背影。我们还发现phospho-histone H3和复审委员会明显增加只有PRI-VIB co-treatment,但不是通过CHL-VIB co-treatment。这表明,减少这些蛋白的表达与降低CHL-VIB G2arrest co-treatment。我们进一步另一种抗疟药物的效果相比,甲氟喹(MEF),结合六anti-mitotic药物。我们发现MEF和PRI有类似的敏化效果与这些anti-mitotic co-treatment药物。 PRI and MEF had generally similar sensitization effects in co-treatment with anti-mitotic drugs, suggesting that they do not have any preferred anti-mitotic drug partner in co-treatment. This indicates that only CHL shows specificity in co-treatment with anti-mitotic drugs in resistant cancer cells. Our results may contribute to the choice of anti-mitotic drugs to be used in co-treatment of resistant cancer cells with the anti-malarial drugs, CHL, PRI, and MEF.